Five-Year Results of TAVR vs. SAVR in Low-Risk Patients

Trial data show similar outcomes at 5 years in selected patients with severe aortic stenosis.

Transcatheter aortic-valve replacement (TAVR) has transformed the care of people with aortic stenosis, but questions remain about long-term outcomes. In the multicenter PARTNER 3 trial, investigators randomized 1000 patients with severe, symptomatic aortic stenosis and low surgical risk to undergo TAVR with the balloon-expandable SAPIEN 3 transcatheter heart valve or surgical aortic-valve replacement (SAVR). The trial showed favorable outcomes with TAVR at 1 year (NEJM JW Cardiol Mar 17 2019 and N Engl J Med 2019; 380:1695). Now, 5-year follow-up results are available.

The mean age of the patients was 73 years, and 69% were men. Vital status was available in 98% of the TAVR group and 97% of the SAVR group. The estimated rate of death, stroke…

Reviewing Author

Harlan M. Krumholz, MD, SM

Disclosures

Consultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime

EquityHugo Health; Refactor Health; Element Science

Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association

Harlan M. Krumholz, MD, SM

Disclosures

Consultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime

EquityHugo Health; Refactor Health; Element Science

Five-Year Results of TAVR vs. SAVR in Low-Risk Patients

Topics

Reviewing Author